Auriga Laboratories, Inc. Announces Innovative Strategic Initiative To Expand Pharmaceutical Sales Force And Revenue Potential At Minimal Costs

NORCROSS, Ga.--(BUSINESS WIRE)--July 31, 2006--Auriga Laboratories, Inc. (OTCBB:ARGA - News), a specialty pharmaceutical company and marketer of the Extendryl® family of products, today announced the launch of an innovative and unique commission-only structure that will allow the Company to expand its sales force significantly within the next 18 months, in a plan designed to maximize revenues while minimizing costs. Auriga is among the first pharmaceutical companies to apply a commission-only structure. While many pharmaceutical companies compensate sales employees with an estimated 70% salary and the remainder in bonus, Auriga's innovative new structure will provide 100 percent commission with an additional performance incentive of stock option grants.